Prevention of venous thromboembolic events in patients with lower leg immobilization after trauma: Systematic review and network meta-analysis with meta-epsidemiological approach release_dwk2dr6wvvbjpddg4psujav7hy

by delphine douillet, C. Chapelle, Edouard Ollier, P. Mismetti, P.-M. Roy, Silvy Laporte

Published in PLoS Medicine by Public Library of Science (PLoS).

2022   Volume 19, Issue 7, e1004059

Abstract

<jats:sec id="sec001"> <jats:title>Background</jats:title> Lower limb trauma requiring immobilization is a significant contributor to overall venous thromboembolism (VTE) burden. The clinical effectiveness of thromboprophylaxis for this indication and the optimal agent strategy are still a matter of debate. Our main objective was to assess the efficacy of pharmacological thromboprophylaxis to prevent VTE in patients with isolated temporary lower limb immobilization after trauma. We aimed to estimate and compare the clinical efficacy and the safety of the different thromboprophylactic treatments to determine the best strategy. </jats:sec> <jats:sec id="sec002"> <jats:title>Methods and findings</jats:title> We conducted a systematic review and a Bayesian network meta-analysis (NMA) including all available randomized trials comparing a pharmacological thromboprophylactic treatment to placebo or to no treatment in patients with leg immobilization after trauma. We searched Medline, Embase, and Web of Science until July 2021. Only RCT or observational studies with analysis of confounding factors including adult patients requiring temporary immobilization for an isolated lower limb injury treated conservatively or surgically and assessing pharmacological thromboprophylactic agents or placebo or no treatment were eligible for inclusion. The primary endpoint was the incidence of major VTE (proximal deep vein thrombosis, symptomatic VTE, and pulmonary embolism-related death). We extracted data according to Preferred Reporting Items for Systematic Reviews and Meta-analyses for NMA and appraised selected trials with the Cochrane review handbook. Fourteen studies were included (8,198 patients). Compared to the control group, rivaroxaban, fondaparinux, and low molecular weight heparins were associated with a significant risk reduction of major VTE with an odds ratio of 0.02 (95% credible interval (CrI) 0.00 to 0.19), 0.22 (95% CrI 0.06 to 0.65), and 0.32 (95% CrI 0.15 to 0.56), respectively. No increase of the major bleeding risk was observed with either treatment. Rivaroxaban has the highest likelihood of being ranked top in terms of efficacy and net clinical benefit. The main limitation is that the network had as many indirect comparisons as direct comparisons. </jats:sec> <jats:sec id="sec003"> <jats:title>Conclusions</jats:title> This NMA confirms the favorable benefit/risk ratio of thromboprophylaxis for patients with leg immobilization after trauma with the highest level of evidence for rivaroxaban. </jats:sec> <jats:sec id="sec004"> <jats:title>Trial registration</jats:title> PROSPERO <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021257669" xlink:type="simple">CRD42021257669</jats:ext-link>. </jats:sec>
In application/xml+jats format

Archived Files and Locations

application/pdf  4.4 MB
file_wcmwh3kcdvdpvbmihfe2m6ad5y
journals.plos.org (publisher)
web.archive.org (webarchive)
Read Archived PDF
Preserved and Accessible
Type  article-journal
Stage   published
Date   2022-07-18
Language   en ?
Journal Metadata
Open Access Publication
In DOAJ
In ISSN ROAD
In Keepers Registry
ISSN-L:  1549-1277
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 9e6f6272-53e0-45bd-ba7d-60a2d7f4fbb9
API URL: JSON